Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 3,494

Document Document Title
WO/2022/168884A1
The present invention provides a novel cationic lipid having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof. (In ...  
WO/2022/160466A1
A 2-cyanoacrylate compound and use thereof for preventing and treating fungal diseases of crops, belonging to the field of fungicides. The 2-cyanoacrylate compound has good fungicidal activity, particularly has good fungicidal activity a...  
WO/2022/156827A1
The present invention relates to an allicin derivative, having the structure as shown in formula I, and a preparation method and use therefor, wherein R1 and R2 are respectively an alkyl group having 1 to 4 carbons, a cycloalkyl group, a...  
WO/2022/155037A1
Disclosed are compounds for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, for example, compounds of formulas (I) and (II), wherein R1‑R8, X, Y, Z, X', Y'...  
WO/2022/152705A1
Compounds of Formula (I) wherein R1, R3, R11, R12, X, Y1, Y2, Y3, Y4 and formula (II) are as defined in the description. Medicaments.  
WO/2022/133040A1
Provided are kinases inhibitors, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, such as methods of treating a proliferation disorder, such as a cancer or a tumor, or in some em...  
WO/2022/127863A1
Provided are a crystal form 2, a crystal form 8, a crystal form 10, and a crystal form 16 of a hemifumarate salt of formula (I), preparation methods therefor, and uses thereof. The crystal form 2, crystal form 8, crystal form 10, and cry...  
WO/2022/127655A1
The present invention provides an NLRP3 inflammasome inhibitor and the use thereof in the preparation of a drug for preventing or treating NLRP3 inflammasome-related diseases. The NLRP3 inflammasome inhibitor of the present invention can...  
WO/2022/107724A1
The present invention provides: a novel azetidinone derivative having excellent herbicidal activity, or a salt thereof; an herbicide containing the same as an active ingredient; and a production intermediate. Provided are: an azetidinone...  
WO/2022/109043A1
Described herein are uses of the CB1 inhibitors (e.g., antagonists, neutral antagonists, inverse agonists) and various methods of using and administering a CB1 inhibitor to a patient, especially patients showing symptoms of drug overdose...  
WO/2022/087008A1
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases. Specific diseases include those that are mediated by YAP/TAZ or those that are modulated by the interaction be...  
WO/2022/084298A1
The present application relates to compounds of formula (I), or pharmaceutically acceptable salts thereof: wherein R1 and R2 represent hydrogen or deuterium; R3 represents hydrogen, -COOH or -OH; R3' and R3" represent hydrogen, methyl, m...  
WO/2022/084280A1
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof wherein R1 and R2 represent a hydrogen atom or a deuterium atom; R3 represents a hydrogen atom, a -COOH group or a -OH group; R3' and R3" rep...  
WO/2022/063784A1
Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods fo...  
WO/2022/064007A1
The presented invention relates to solid forms of Siponimod adipic acid salt and cocrystal.  
WO/2022/067114A1
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disor...  
WO/2022/059684A1
Provided is a vitamin D derivative demonstrating excellent central nervous system migration, or a pharmaceutically acceptable salt or a solvate thereof. Specifically provided is a vitamin D derivative represented by formula (1), or a p...  
WO/2022/056045A1
The present disclosure provides SPNS2 inhibitor compounds according to Formula (IA) and Formula (I), and their pharmaceutically acceptable salts, and/or tautomers as described in the disclosure, and the disclosure provides their pharmace...  
WO/2022/040172A1
The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.  
WO/2022/029598A1
The invention discloses a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof that binds tightly to a hydrophobic binding pocket of Mdm2, preventing binding of Mdm2 to the tumour suppressor p53 and increasing p53 ...  
WO/2022/022612A1
The invention relates to novel glutamine analogs shown as the formula I, a composition containing the glutamine analogs and the use thereof.  
WO/2022/026500A1
Disclosed are compounds of Formula 1, all stereoisomers, N-oxides and salts thereof, wherein G is CONR5R6 or selected from and R1 through R18 Rf and G are as defined in the Disclosure. Also disclosed are compositions containing the compo...  
WO/2022/020222A1
The present invention is directed to compositions containing a fatty acid amide hydrolase inhibitor and methods of use thereof for treatment of trauma-related psychiatric disorders in a patient in need thereof, particularly those that ex...  
WO/2022/013408A2
The present invention relates to cyclic cyanoenone derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4 and m are as defined herein. The present invention also relates to pharmaceuti...  
WO/2021/262483A1
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present inven...  
WO/2021/262541A1
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present d...  
WO/2021/251337A1
CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compo...  
WO/2021/240547A2
The present invention relates to process for preparation of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxy imino]ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid, intermediates, salts and solid forms thereof to pharmaceutical co...  
WO/2021/243093A1
The described invention provides compositions and methods for improving or restoring immune system health in a susceptible subject and/or a subject infected with a respiratory virus that impacts the immune system by reducing functional d...  
WO/2021/236771A1
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-Ll or the PD-1/PD-Ll interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...  
WO/2021/233396A1
Provided are azetidine cyclic urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomer...  
WO/2021/226276A2
Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a ph...  
WO/2021/214502A1
The present application provides a method of preparing 4-[3-{3-[(cyclopropylamino)methyl]azetidine-1-carbonyl)-4-fl uorobenzyl]phthalazin-1(2H)-one, or a pharmaceutically acceptable sail thereof, intermediates in the preparation thereof,...  
WO/2021/209268A1
The invention relates to compounds of formula (I), and their use as herbicides. In said formula, R1 to R9 represent groups such as hydrogen, halo-gen or organic groups such as alkyl, alkenyl, alkynyl, or alkoxy; X is a bond or a divalent...  
WO/2021/204175A1
Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid...  
WO/2021/202781A1
Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, n, R1, R2, R6, R7, R8, R9, R10, X3, X4 and X5 are defined in the specification. This disclosure also relates to materials and methods for pre...  
WO/2021/195183A1
The invention provides compounds that are inhibitors of the protein embryonic ectoderm development (EED), pharmaceutical compositions, their use in modulating the activity of EED, and their use in the treatment of medical disorders, such...  
WO/2021/161887A1
[Problem] To provide a novel compound which has high absorption selectivity for the long-wavelength ultraviolet to near ultraviolet region close to a wavelength of 400 nm, exhibits high weathering resistance, and has a merocyanine skelet...  
WO/2021/160680A1
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.  
WO/2021/160920A1
Dendrimer-based nanostructures for the diagnosis of allergies to beta-lactam antibiotics and applications. The structure has the formula B-D-L-H-L-D-B, where: H is a hydrophilic polymer (PEG), L is a linker (maleimide), D is a dendrimer ...  
WO/2021/159015A1
Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formul...  
WO/2021/150885A1
This disclosure provides 8,9-dihydrocannabinoid derivatives, deuterated cannabinoid derivatives, and tritiated cannabinoid derivatives. The disclosure also provides compositions, methods of use, and processes of preparation of the forego...  
WO/2021/147818A1
A compound of a structure of formula I having a central nervous system disease treatment effect, which has the activity of a 5-HT2A receptor antagonist or an inverse agonist, has high 5-HT2A receptor selectivity, low cardiotoxicity, and ...  
WO/2021/141969A1
Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve t...  
WO/2021/112251A1
The present invention addresses the problem of providing a compound that serves as a useful therapeutic medication for systemic lupus erythematosus (SLE) and autoimmune diseases, such as lupus nephritis, in SLE patients by suppressing im...  
WO/2021/106230A1
Provided is a phenol compound, or a salt thereof, represented by general formula (I). (In the formula, R1、R2、R5、L1、L2、L3、A、 X、and m are as defined in the description.)  
WO/2021/097351A1
Methods, compounds and compositions for treating and preventing dermatological disorders and ocular irritancy are disclosed. The compounds and compositions comprise a functionalized 1,3-benzene diol, such as 5-(2-(1H-1,2,3-triazol-1-yl)e...  
WO/2021/083209A1
Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of...  
WO/2021/078073A1
Provided are an N-containing derivative of substituted phenol hydroxy acid ester, and the preparation and use thereof. A compound is represented by formula (I). A salt of the compound of formula (I) has good water solubility, and, in viv...  
WO/2021/081141A1
Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthas...  

Matches 1 - 50 out of 3,494